HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature.

Gevorgyan, Arpine; Bregni, Giacomo; Galli, Giulia; Zanardi, Elisa; de Braud, Filippo; Di Cosimo, Serena

Gevorgyan, Arpine; Bregni, Giacomo; Galli, Giulia; Zanardi, Elisa; de Braud, Filippo; Di Cosimo, Serena.

Afiliação

Gevorgyan A; Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.
Bregni G; Medical Oncology Unit 1, IRCCS AOU San Martino-IST, Genoa, Italy.
Galli G; Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.
Zanardi E; Medical Oncology Unit 1, IRCCS AOU San Martino-IST, Genoa, Italy.
de Braud F; Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.
Di Cosimo S; Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.

Breast Care (Basel) ; 11(6): 424-426, 2016 Dec.

Article em En | MEDLINE | ID: mdl-28228710

RESUMO

BACKGROUND: Neuroendocrine carcinoma is an uncommon histology for breast cancer. CASE REPORT: Our patient underwent right quadrantectomy for a neuroendocrine carcinoma in 1984 and had a bone relapse 30 years later. After thorough pathological and immunohistochemical analysis the diagnosis was confirmed and HER2 amplification was observed. Here we discuss the management, rationale and results of HER2-targeted therapy in advanced neuroendocrine breast carcinoma.

Palavras-chave

Breast carcinoma; Neuroendocrine carcinoma; Trastuzumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links